Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 31Advanced Solid Tumors 25Advanced Solid Tumor 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 15Solid Tumor 12Prostatic Neoplasms 12Multiple Myeloma 12Neoplasm Metastasis 11Recurrence 10Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Lung Neoplasms 9Stomach Neoplasms 8Melanoma 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Sarcoma 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Solid Tumors 6Carcinoma, Transitional Cell 5Advanced Solid Tumour 5Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Myelodysplastic Syndromes 4Lymphoma 4

Interventions

Irinotecan 2Injections 2vistusertib 1urelumab 1sapanisertib 1pembrolizumab 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1ZD4054 1Rosuvastatin Calcium 1Rabeprazole 1Metformin 1HM781-36B 1Furosemide 1Digoxin 1ATP Binding Cassette Transporter, Subfamily B, Member 1 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Malignancies × Injections × Clear all
NCT07368478 2026-01-26

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Biocity Biopharmaceutics Co., Ltd.

Phase 1 Recruiting
180 enrolled

Advanced Solid Malignancies

NCT06388902 2025-11-21

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

BioRay Pharmaceutical Co., Ltd.

Phase 1 Suspended
120 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡